Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Capital Expenditures: 2012-2023

Historic Capital Expenditures for Coherus Oncology (CHRS) over the last 12 years, with Dec 2023 value amounting to $286,000.

  • Coherus Oncology's Capital Expenditures fell 1108.50% to -$483.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$706.5 million, marking a year-over-year decrease of 210.29%. This contributed to the annual value of $286,000 for FY2023, which is 85.97% down from last year.
  • Latest data reveals that Coherus Oncology reported Capital Expenditures of $286,000 as of FY2023, which was down 85.97% from $2.0 million recorded in FY2022.
  • In the past 5 years, Coherus Oncology's Capital Expenditures ranged from a high of $7.2 million in FY2020 and a low of $286,000 during FY2023.
  • For the 3-year period, Coherus Oncology's Capital Expenditures averaged around $1.2 million, with its median value being $1.3 million (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 296.87% in 2020, then plummeted by 85.97% in 2023.
  • Over the past 5 years, Coherus Oncology's Capital Expenditures (Yearly) stood at $1.8 million in 2019, then spiked by 296.87% to $7.2 million in 2020, then slumped by 82.17% to $1.3 million in 2021, then soared by 58.18% to $2.0 million in 2022, then crashed by 85.97% to $286,000 in 2023.